Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

Cancer Immunity

Volumn 10, Issue , 2010, Pages

  Yuan, Jianda ^a   Page, David B ^a   Ku, Geoffrey Y ^a   Li, Yanyun ^a   Mu, Zhenyu ^a   Ariyan, Charlotte ^a   Gallardo, Humilidad F ^a   Roman, Ruth Ann ^a   Heine, Agnes I ^a   Terzulli, Stephanie L ^a   Gnjatic, Sacha ^b   Ritter, Gerd ^b   Jungbluth, Achim A ^b   Allison, James P ^a   Old, Lloyd J ^b   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Case report; Human; Immunoediting; Immunogram; Ipilimumab; Melanoma

Indexed keywords

CORTICOSTEROID; IPILIMUMAB; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANTIBODY TITER; ARTICLE; BONE METASTASIS; CANCER CONTROL; CANCER INFILTRATION; CANCER SURGERY; CANCER THERAPY; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MELANOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; TREATMENT RESPONSE;

EID: 76149137243     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465. (PMID: 7543139)
2. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440. (PMID: 10795741)
3. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-2550. (PMID: 8676075)
4. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813-5820. (PMID: 10229815)
5. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996; 184: 783-788. (PMID: 8760834)
6. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-366. (PMID: 10430624)
7. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175: 7746-7754. (PMID: 16301685)
8. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116: 1935-1945. (PMID: 16778987)
9. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206: 1717-1725. (PMID: 19581407)
10. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study. Lancet Oncol [Epub ahead of print] (PMID: 20004617)
11. Berman DM, Wolchok J, Weber J, Hamid O, O'Day S, Chasalow SD. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab [abstract]. J Clin Oncol (ASCO Annual Meeting) 2009; 27 (15S): 3020.
12. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, Chapman PD, Schwartz GK, Allison JP, Wolchok JD. Compassionate-use trial of ipilimumab in patients with advanced melanoma: lymphocyte count after two doses correlates with survival. Cancer 2009; in press.
13. Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2008; 123: 2362-2369. (PMID: 18729190)
14. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T cell activation and function. Nature 2001; 409: 97-101. (PMID: 11343121)
15. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263-266. (PMID: 9930702)
16. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105: 14987-14992. (PMID: 18818309)
17. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061. (PMID: 12522256)
18. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008; 112: 1175-1183. (PMID: 18523152)
19. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625. (PMID: 16034368)
20. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30. (PMID: 16860654)
21. Gnjatic S, Atanackovic D, Matsuo M, Jäger E, Lee SY, Valmori D, Chen YT, Ritter G, Knuth A, Old LJ. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol 2003; 170: 1191-1196. (PMID: 12538675)
22. Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97: 12198-12203. (PMID: 11027314)
23. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008; 105: 20410-20415. (PMID: 19074257)
24. Amin A, DePril V, Hamid O, Wolchok J, Maio M, Neyns B, Chin K, Ibrahim R, Hoos A, O'Day S. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity [abstract]. J Clin Oncol (ASCO Annual Meeting) 2009; 27 (15S): 9037.
25. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688. (PMID: 17982122)
26. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008; 8: 1. URL: http://www.cancerimmunity.org/v8p1/ 080102.htm
27. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360. (PMID: 15032581)
28. Yuan J, Gnjatic S, Ku G, Jefferson M, Tandon S, Ritter E, Rasalan TS, Orlandi F, Li H, Gallardo HF, Xu YY, Ritter G, Scher H, Lowy I, Old LJ, Wolchok JD, Slovin SF, Allison JP. NY-ESO-1 specific responses in patients with advanced prostate cancer treated with ipilimumab [abstract]. International Society for Biological Therapy of Cancer Annual Meeting 2009; URL: http://www.isbtc.org/meetings/am09/28
29. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-615. (PMID: 19147575)
30. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12: 764-771. (PMID: 16467087)